SLC5A2 and limb ischemia: Given the important role that EC dysfunction plays in promoting diabetes-associated vascular disease and limb ischemia and the discrepant impact of canagliflozin on limb amputation, the present study tested the hypothesis that canagliflozin, but not other SGLT2 inhibitors, impairs EC function and angiogenesis.